An unusual infection with long-term bevacizumab treatment for advanced nonsmall-cell lung cancer: Actinomycosis

Bevacizumab is an angiogenesis inhibitor with Food and Drug Administration approval for multiple tumor types (including colon, nonsquamous nonsmall-cell lung cancer, kidney and glioblastoma multiforme, cervix, and ovarian cancer). Here, we present a patient with actinomycosis who was on treatment wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2022-10, Vol.18 (6), p.1809-1810
Main Authors: Erol, Cihan, Nahit Sendur, Mehmet, Yalçin, Bülent
Format: Article
Language:English
Subjects:
Actinomycosis
Actinomycosis - diagnosis
Actinomycosis - drug therapy
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - therapeutic use
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Care and treatment
Case studies
Complications and side effects
Development and progression
Drug therapy
Female
Humans
Inhibitor drugs
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Monoclonal antibodies
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab is an angiogenesis inhibitor with Food and Drug Administration approval for multiple tumor types (including colon, nonsquamous nonsmall-cell lung cancer, kidney and glioblastoma multiforme, cervix, and ovarian cancer). Here, we present a patient with actinomycosis who was on treatment with bevacizumab maintenance therapy following chemotherapy combined with bevacizumab. A 60-year-old male patient with lung adenocarcinoma was treated four cycles of carboplatin, paclitaxel with bevacizumab. And then, bevacizumab maintenance therapy was continued. After 38 months of bevacizumab maintenance, computed tomography showed a newly developed cavitary lesion in the upper lobe of the right lung. Bronchoscopy was performed and the pathology report of the biopsy was reported as actinomycosis. Bevacizumab treatment was discontinued and the patient was treated with amoxicillin-clavulanate. To our knowledge, our case is the first case of actinomycosis infection due to the possible bevacizumab treatment.
ISSN:0973-1482
1998-4138
1998-4138
DOI:10.4103/jcrt.jcrt_2083_21